Fingolimod placebo

OTHER3 trials

Sponsors

Tg Therapeutics Inc., Novartis Pharmaceuticals, Hoffmann-La Roche

Conditions

Multiple Sclerosis (MS)Relapsing Multiple SclerosisRelapsing-Remitting Multiple Sclerosis

Phase 2

Ublituximab in Pediatric Participants with Relapsing forms of Multiple Sclerosis (RMS)

Not yet recruitingCTIS2025-522257-19-00

Tg Therapeutics Inc.Relapsing Multiple Sclerosis

Target: 40Updated: 2025-12-22

Phase 3

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

Active, not recruitingNCT04926818

Novartis PharmaceuticalsMultiple Sclerosis (MS)

Start: 2021-10-05End: 2031-03-06Updated: 2026-03-30

A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)

Active, not recruitingNCT05123703

Hoffmann-La RocheRelapsing-Remitting Multiple Sclerosis

Start: 2022-05-19End: 2029-09-17Updated: 2026-01-30

Related Papers

Ocrelizumab dose selection for treatment of pediatric relapsing–remitting multiple sclerosis: results of the OPERETTA I study

Journal of Neurology2025-01-156 citations